SPECTRUM PHARMACEUTICALS INC Form 8-K November 23, 2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 21, 2012

SPECTRUM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other Jurisdiction

001-35006 (Commission 93-0979187 (IRS Employer


of Incorporation) File Number) Identification No.)

11500 S. Eastern Ave., Ste. 240,

Henderson, NV 89052
(Address of Principal Executive Offices) (Zip Code)
Registrant s telephone number, including area code: (702) 835-6300

Not Applicable

(Former name or former address if changed since last report.)



- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On November 21, 2012, Spectrum Pharmaceuticals, Inc. (the <u>Company</u>), filed a replacement registration statement on Form S-3 (the <u>New Registration Statement</u>) to cover an aggregate of up to \$250,000,000 of securities that were never sold under a previously filed registration statement on Form S-3 (File No. 333-163366) filed on November 25, 2009 that was not used. That Registration Statement is set to expire on January 12, 2013 (the <u>Expiring Registration Statement</u>). The purpose of the New Registration Statement is to just replace the Expiring Registration Statement and effectively extend the Company s benefits of registration for an additional 3 year period. The Expiring Registration Statement will be deemed terminated automatically as of the effective date of the New Registration Statement.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 21, 2012

SPECTRUM PHARMACEUTICALS, INC.

By: /s/ Brett L. Scott Senior Vice President and Acting Chief Financial Officer